Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for heart failure
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Home-based telerehabilitation is not inferior to a centre-based program in patients with chronic heart failure: a randomised trial 28336297 2017 03 24 2017 04 23 1836-9561 63 2 2017 Apr Journal of physiotherapy J Physiother Home-based telerehabilitation is not inferior to a centre-based program in patients with chronic heart failure: a randomised trial. 101-107 S1836-9553(17)30031-0 10.1016/j.jphys.2017.02.017 Is a 12-week, home-based telerehabilitation program conducted in small groups non (...) -inferior to a traditional centre-based program in terms of the change in 6-minute walk distance? Is the telerehabilitation program also non-inferior to a centre-based program in terms of functional capacity, muscle strength, quality of life, urinary incontinence, patient satisfaction, attendance rates, and adverse events? Randomised, parallel, non-inferiority trial with concealed allocation, intention-to-treat analysis and assessor blinding. Patients with stable chronic heart failure (includingheart failure
Heart failure. Heart failureis common in adults, accounting for substantial morbidity and mortality worldwide. Its prevalence is increasing because of ageing of the population and improved treatment of acute cardiovascular events, despite the efficacy of many therapies for patients with heart failurewith reduced ejection fraction, such as angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), β blockers, and mineralocorticoid receptor antagonists, and advanced (...) device therapies. Combined angiotensin receptor blocker neprilysin inhibitors (ARNIs) have been associated with improvements in hospital admissions and mortality from heart failurecompared with enalapril, and guidelines now recommend substitution of ACE inhibitors or ARBs with ARNIs in appropriate patients. Improved safety of left ventricular assist devices means that these are becoming more commonly used in patients with severe symptoms. Antidiabetic therapies might further improve outcomes
Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. Background In patients with acute heart failure, early intervention with an intravenous vasodilator has been proposed as a therapeutic goal to reduce cardiac-wall stress and, potentially, myocardial injury, thereby favorably affecting patients' long-term prognosis. Methods In this double-blind trial, we randomly assigned 2157 patients with acute heart failureto receive a continuous intravenous infusion of either ularitide (...) % of patients with paired data. Conclusions In patients with acute heart failure, ularitide exerted favorable physiological effects (without affecting cardiac troponin levels), but short-term treatment did not affect a clinical composite end point or reduce long-term cardiovascular mortality. (Funded by Cardiorentis; TRUE-AHF ClinicalTrials.gov number, NCT01661634 .).
Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HFTrial28335841 2017 03 24 2017 03 24 1558-3597 69 12 2017 Mar 28 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HFTrial. 1577-1587 S0735-1097(17)30439-4 10.1016/j.jacc.2017.01.041 Sleep apnea is common in hospitalized heart failure (HF (...) ) patientsand is associated with increased morbidity and mortality. The CAT-HF (CardiovascularImprovements With MV-ASV Therapy in Heart Failure) trial investigated whether minute ventilation (MV) adaptive servo-ventilation (ASV) improved cardiovascular outcomes in hospitalized HFpatientswith moderate-to-severe sleep apnea. Eligible patients hospitalized with HFandmoderate-to-severe sleep apnea were randomized to ASV plus optimized medical therapy (OMT) or OMT alone (control). The primary endpoint
Association Between Rheumatoid Arthritis and Risk of Ischemic and Nonischemic Heart Failure28279294 2017 03 10 2017 03 10 1558-3597 69 10 2017 Mar 14 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Association Between Rheumatoid Arthritis and Risk of Ischemic and Nonischemic Heart Failure. 1275-1285 S0735-1097(17)30196-1 10.1016/j.jacc.2016.12.033 It is unknown whether the increased risk of heart failure (HF) inrheumatoid arthritis (RA) is independent of ischemic heart (...) disease (IHD). This study sought to investigate the relative risk of HFoveralland by subtype (ischemic and nonischemic HF) inpatients with RA and to assess the impact of RA disease factors. Two contemporary cohorts of RA subjects were identified from Swedish patient and rheumatology registries and matched 1:10 to general population comparator subjects. A first-ever HFdiagnosis (classified as ischemic HFornonischemicHFbasedon the presence of IHD) was assessed through registry linkages. Relative
Metabolic profiles in heart failuredue to nonâ€ischemic cardiomyopathy at rest and under exercise 28451455 2018 11 13 2055-5822 4 2 2017 May ESC heart failureESCHeart Fail Metabolic profiles in heart failuredue to non-ischemic cardiomyopathy at rest and under exercise. 178-189 10.1002/ehf2.12133 Identification of metabolic signatures in heart failure (HF) patientsand evaluation of their diagnostic potential to discriminate HFpatientsfrom healthy controls during baseline and exercise (...) conditions. Plasma samples were collected from 22 male HFpatientswith non-ischemic idiopathic cardiomyopathy and left ventricular systolic dysfunction and 19 healthy controls before (t0), at peak (t1) and 1 h after (t2) symptom-limited cardiopulmonary exercise testing. Two hundred fifty-two metabolites were quantified by gas chromatography-mass spectrometry (GC-MS) and liquid chromatography (LC)-MS/MS-based metabolite profiling. Plasma metabolite profiles clearly differed between HFpatientsand
Differentiating heart failurephenotypes using sexâ€specific transcriptomic and proteomic biomarker panels 28772032 2018 11 13 2055-5822 4 3 2017 Aug ESC heart failureESCHeart Fail Differentiating heart failurephenotypes using sex-specific transcriptomic and proteomic biomarker panels. 301-311 10.1002/ehf2.12136 Heart failurewith preserved ejection fraction (HFpEF) accounts for 30-50% of patients with heart failure (HF). Amajor obstacle in HFmanagementis the difficulty (...) in differentiating between HFpEF and heart failurewith reduced ejection fraction (HFrEF) using conventional clinical and laboratory investigations. The aim of this study is to develop robust transcriptomic and proteomic biomarker signatures that can differentiate HFpEF from HFrEF. A total of 210 HFpatientswere recruited in participating institutions from the Alberta HEART study. An expert clinical adjudicating panel differentiated between patients with HFpEF and HFrEF. The discovery cohort consisted of 61
Periodontitis and bone metabolism in patients with advanced heart failureand after heart transplantation 28451454 2018 11 13 2055-5822 4 2 2017 May ESC heart failureESCHeart Fail Periodontitis and bone metabolism in patients with advanced heart failureand after heart transplantation. 169-177 10.1002/ehf2.12126 Heart failure (HF) isa multi-organ, pro-inflammatory syndrome that impairs bone metabolism. Pro-inflammatory cytokines and bone catabolism enhance periodontal disease, a local (...) inflammatory, bacteria-induced disease that causes bone loss and periodontal soft tissue destruction. Medical and dental examinations were performed on patients with HF ( n = 39), following heart transplantation (post-HTx, n = 38) and controls ( n = 32). Blood, saliva, and gingival crevicular fluid were analysed for bone metabolism and inflammation markers. HFaverageNew York Heart Association classification was III. Average time since HTx was 1414 days. Pro-inflammatory tumour necrosis factor-alpha
Abnormal haemodynamic postural response in patients with chronic heart failure28451451 2018 11 13 2055-5822 4 2 2017 May ESC heart failureESCHeart Fail Abnormal haemodynamic postural response in patients with chronic heart failure. 146-153 10.1002/ehf2.12127 The objective was to evaluate in treated heart failure (HF) patientswhether multidrug therapy interferes with the cardiovascular autonomic response to postural stress. Blood pressure (BP; Finapres), heart rate (HR), stroke volume (...) , and total peripheral resistance (TPR) responses to standing up were measured in 33 HFpatientsand 10 healthy age-matched controls. Ten hypertensive (HT) patients treated with a similar combination of drugs but without heart failureserved as reference subjects to account for use of medication. Frequency domain measures of HR and BP variability were calculated as correlates of cardiovascular autonomic function. Postural hypotension was found in 16 out of 33 HFpatientsindependently from New York Heart
On admission serum sodium and uric acid levels predict 30Â day rehospitalization or death in patients with acute decompensated heart failure28451453 2018 11 13 2055-5822 4 2 2017 May ESC heart failureESCHeart Fail On admission serum sodium and uric acid levels predict 30 day rehospitalization or death in patients with acute decompensated heart failure. 162-168 10.1002/ehf2.12135 A considerable proportion of hospitalized patients for acute decompensated heart failurewill be readmitted or die (...) in short-term follow-up. In the present study, we aimed to assess the role of admission sodium (Na) and uric acid (UA) levels in the prediction of 30 day post-discharge heart failurereadmission or all-cause mortality in advanced heart failurepatients admitted with acute decompensation. One hundred and forty consecutive advanced heart failurepatients who were admitted for a recent cardiac decompensationwere enrolled in this prospective study. Serum Na and UA levels remained statistically unchanged
Kyoto Congestive Heart Failure (KCHF) study: rationale and design 28772047 2018 11 13 2055-5822 4 3 2017 Aug ESC heart failureESCHeart Fail Kyoto Congestive Heart Failure (KCHF) study: rationale and design. 216-223 10.1002/ehf2.12138 Over the last decade, major developments in medicine have led to significant changes in the clinical management of heart failurepatients. This study was designed to evaluate the recent trends in clinical characteristics, management, and short-term and long-term (...) prognosis of patients with acute decompensated heart failure (ADHF) in Japan. The Kyoto Congestive Heart Failurestudy is a prospective, observational, multicentre cohort study, enrolling consecutive ADHF patients from 19 participating hospitals in Japan from November 2014 to March 2016. A total of 4000 patients will be enrolled into the study and patients' anthropometric, socio-economic, and clinical data from hospital admission to discharge will be collected. In addition, in a pre-determined subgroup
Value of Cardiovascular Magnetic Resonance Imagingâ€“Derived Baseline Left Ventricular Ejection Fraction and Volumes for Precise Risk Stratification of Patients With Ischemic Cardiomyopathy: Insights From the Surgical Treatment for Ischemic Heart Failure28199489 2018 11 13 2380-6591 2 5 2017 May 01 JAMA cardiology JAMA Cardiol Value of Cardiovascular Magnetic Resonance Imaging-Derived Baseline Left Ventricular Ejection Fraction and Volumes for Precise Risk Stratification of Patients (...) With Ischemic Cardiomyopathy: Insights From the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. 577-579 10.1001/jamacardio.2016.5492 Pai Ramdas G RG Department of Medicine/Cardiology, University of California, Riverside School of Medicine, Riverside. Varadarajan Padmini P Department of Medicine/Cardiology, Loma Linda University, Loma Linda, California. Rouleau Jean L JL Department of Medicine/Cardiology, Montréal Heart Institute, Université de Montréal, Montréal, Quebec, Canada. Stebbins Amanda
Risk of heart failureafter community acquired pneumonia: prospective controlled study with 10 years of follow-up. Objective To determine the attributable risk of community acquired pneumonia on incidence of heart failurethroughout the age range of affected patients and severity of the infection. Design Cohort study. Setting Six hospitals and seven emergency departments in Edmonton, Alberta, Canada, 2000-02. Participants 4988 adults with community acquired pneumonia and no history of heart failure (...) were prospectively recruited and matched on age, sex, and setting of treatment (inpatient or outpatient) with up to five adults without pneumonia (controls) or prevalent heart failure (n=23 060). Main outcome measures Risk of hospital admission for incident heart failureor a combined endpoint of heart failureor death up to 2012, evaluated using multivariable Cox proportional hazards analyses. Results The average age of participants was 55 years, 2649 (53.1%) were men, and 63.4% were managed
Association between matrix metalloproteinaseâ€9 and worsening heart failureevents in patients with chronic heart failure28772055 2018 11 13 2055-5822 4 3 2017 Aug ESC heart failureESCHeart Fail Association between matrix metalloproteinase-9 and worsening heart failureevents in patients with chronic heart failure. 321-330 10.1002/ehf2.12137 Matrix metalloproteinase (MMP) is up-regulated during heart failure (HF) andinfluences ventricular remodeling. We hypothesized that disparity between (...) MMP-9 and tissue inhibitors of MMP-1 (TIMP-1) results in clinical manifestations and is related to prognostic risk in patients with chronic HF. Plasmalevels of MMP-9, TIMP-1, and brain natriuretic peptide (BNP) were measured in 173 patients with chronic HF. Combinedendpoints of worsening HFeventswere assessed during follow-up (median 109 months). MMP-9 and TIMP-1 levels and the MMP-9/TIMP-1 ratio increased with increasing severity of the New York Heart Association class (P for trend = 0.003
Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure. BACKGROUND: Mechanical circulatory support with a left ventricular assist device (LVAD) is an established treatment for patients with advanced heart failure. We compared a newer LVAD design (a small intrapericardial centrifugal-flow device) against existing technology (a commercially available axial-flow device) in patients with advanced heart failurewho were ineligible for heart transplantation. METHODS: We conducted (...) , 12.56 percentage points; P=0.01 for noninferiority). More patients in the control group than in the study group had device malfunction or device failure requiring replacement (16.2% vs. 8.8%), and more patients in the study group had strokes (29.7% vs. 12.1%). Quality of life and functional capacity improved to a similar degree in the two groups. CONCLUSIONS: In this trial involving patients with advanced heart failurewho were ineligible for heart transplantation, a small, intrapericardial